← Leaderboards
Denise E Sabatino
Children'S Hosp Of Philadelphia
$7,291,515
Attributed
$8,568,647
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,568,647 · 6
By mechanism
R01$8,122,848 · 4
P01$401,587 · 1
F32$44,212 · 1
Top collaborators
- Frederic D Bushman4 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Frederic D Bushman$38,686,561
Others in their field
Top investigators on “Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Mark A Kay · Stanford University$49,905,067
Research focus
LiverCapsidGene TherapyAdeno-Associated Viral VectorDoseViralFactor ViiiVectorImmune ResponseSafetyHemophilia ABlood Coagulation DisordersLinkGene DeliveryTransgenesProteinsPreventF8 GeneCellsGene TransferBiologicalMediatingEngineeringSite
Grant awards (16)
Endothelial cell targeting of factor VIII for hemophilia A$888,836
R01 · FY2025 · HL · contact PI
Preserving Genome Integrity In AAV-Mediated Gene Therapy$645,239
R01 · FY2025 · HL · contact PI
Preserving Genome Integrity In AAV-Mediated Gene Therapy$632,334
R01 · FY2024 · HL · contact PI
Preserving Genome Integrity In AAV-Mediated Gene Therapy$645,239
R01 · FY2023 · HL · contact PI
Targeted expression of factor VIII in liver sinusoidal endothelial cells for gene therapy for hemophilia A$641,067
R01 · FY2023 · HL · contact PI
Targeted expression of factor VIII in liver sinusoidal endothelial cells for gene therapy for hemophilia A$641,067
R01 · FY2022 · HL · contact PI
Preserving Genome Integrity In AAV-Mediated Gene Therapy$631,452
R01 · FY2022 · HL · contact PI
Targeted expression of factor VIII in liver sinusoidal endothelial cells for gene therapy for hemophilia A$641,067
R01 · FY2021 · HL · contact PI
Targeted expression of factor VIII in liver sinusoidal endothelial cells for gene therapy for hemophilia A$656,547
R01 · FY2020 · HL · contact PI
Novel factor VIII variants for improved efficacy in gene therapy for hemophilia A$420,000
R01 · FY2020 · HL · contact PI
Novel factor VIII variants for improved efficacy in gene therapy for hemophilia A$420,000
R01 · FY2019 · HL · contact PI
Novel factor VIII variants for improved efficacy in gene therapy for hemophilia A$420,000
R01 · FY2018 · HL · contact PI
Novel factor VIII variants for improved efficacy in gene therapy for hemophilia A$420,000
R01 · FY2017 · HL · contact PI
Novel factor VIII variants for improved efficacy in gene therapy for hemophilia A$420,000
R01 · FY2016 · HL · contact PI
Immune Responses to Capsid in AAV-Mediated Gene Transfer$401,587
P01 · FY2014 · HL · contact PI
Immune Tolerance to Factor IX in Hemophilia B$44,212
F32 · FY2002 · HL